| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70934-0831-21 | 70934-0831 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 25, 2021 | In Use | |
| 64980-0337-05 | 64980-0337 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 17, 2017 | In Use | |
| 54868-1183-07 | 54868-1183 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 19, 2003 | In Use | |
| 69238-2811-02 | 69238-2811 | Etoposide | VePesid | 50.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Oral | May 15, 2026 | In Use | |
| 51407-0872-12 | 51407-0872 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lek, c-Fms | Oral | Jan 8, 2024 | In Use | |
| 73591-5886-02 | 73591-5886 | CALCIUM FOLINATE | LEDERLE LEUCOVORIN | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Nov 26, 2025 | In Use | |
| 68071-2781-02 | 68071-2781 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 6, 2022 | In Use | |
| 59572-0205-97 | 59572-0205 | Thalidomide | Thalomid | 50.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jan 26, 2011 | In Use | |
| 55150-0496-10 | 55150-0496 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Apr 8, 2022 | In Use | |
| 62332-0567-90 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 00003-3120-01 | 00003-3120 | Nivolumab and hyaluronidase-nvhy | OPDIVO QVANTIG | 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Nov 24, 2025 | In Use | |
| 70121-2250-01 | 70121-2250 | ROMIDEPSIN | ROMIDEPSIN | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jun 2, 2026 | In Use | |
| 70771-1902-06 | 70771-1902 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 72789-0413-30 | 72789-0413 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 8, 2024 | In Use | |
| 53217-0292-00 | 53217-0292 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 29, 2001 | In Use | |
| 59572-0415-00 | 59572-0415 | Lenalidomide | Revlimid | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jul 7, 2006 | In Use | |
| 75840-0111-00 | 75840-0111 | Methotrexate sodium | Methotrexate Sodium | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct 1, 2012 | In Use | |
| 00078-0669-13 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | Jan 31, 2026 | In Use |
| 72603-0273-01 | 72603-0273 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Jul 10, 2024 | In Use | ||
| 73190-0034-11 | 73190-0034 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 2, 2026 | In Use | |
| 00338-9581-02 | 00338-9581 | Doxorubicin hydrochloride | Doxorubicin hydrochloride, Liposomal | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec 19, 2023 | In Use | |
| 64679-0794-03 | 64679-0794 | imatinib mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 17, 2019 | In Use | |
| 53217-0292-60 | 53217-0292 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 29, 2001 | In Use | |
| 72205-0050-30 | 72205-0050 | Toremifene citrate | Toremifene citrate | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Sep 2, 2020 | In Use | ||
| 55150-0336-01 | 55150-0336 | TESTOSTERONE ENANTHATE | TESTOSTERONE ENANTHATE | 200.0 mg/mL | Hormonal Therapy | Androgen | Intramuscular | Feb 28, 2024 | In Use |
Found 12482 results — Export these results
Home